Short answer
TANDEM DIABETES CARE INC (TNDM) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $255M (up 5.8% year over year) with net income of −$21M.
Q2 2026 key financials · XBRL
- Revenue
- $255M
- +5.8% YoY · +3.0% QoQ
- Net income
- −$21M
- +59.6% YoY · −3.8% QoQ
- Operating margin
- -5.4%
- Gross margin
- 56.9%
- EPS (diluted)
- −$0.30
- +61.0% YoY · +0.0% QoQ
Source: XBRL data from the TANDEM DIABETES CARE INC (TNDM) Q2 2026 10-Q on SEC EDGAR. USD.
TANDEM DIABETES CARE INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Accumulated deficit $1.3 billion as of June 30, 2026, with continued uncertainty around sustained profitability
- CMS competitive bidding finalized December 2, 2025, potentially lowering reimbursement and shifting insulin-pump payments to monthly rentals
- Pharmacy-channel strategy replacing upfront pump reimbursement, creating near-term sales and gross-profit declines at shipment
- GLP-1 adoption since 2023 likely reducing insulin-therapy demand and pressuring pump-market growth
- Nearly all sales depend on insulin pumps, cartridges, and infusion sets, creating concentrated product exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TANDEM DIABETES CARE INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.